Cargando…

Dissection of Agonistic and Blocking Effects of CD200 Receptor Antibodies

The CD200 receptor (CD200R) is present mainly on myeloid cells and gives inhibitory signals when engaged by its ligand CD200. The interaction is currently of therapeutic interest in cancer and inflammation. However functional effects are complicated by the fact that CD200R is itself polymorphic and...

Descripción completa

Detalles Bibliográficos
Autores principales: Akkaya, Munir, Aknin, Marie-Laure, Akkaya, Billur, Barclay, A. Neil
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3653949/
https://www.ncbi.nlm.nih.gov/pubmed/23691022
http://dx.doi.org/10.1371/journal.pone.0063325
_version_ 1782269482705616896
author Akkaya, Munir
Aknin, Marie-Laure
Akkaya, Billur
Barclay, A. Neil
author_facet Akkaya, Munir
Aknin, Marie-Laure
Akkaya, Billur
Barclay, A. Neil
author_sort Akkaya, Munir
collection PubMed
description The CD200 receptor (CD200R) is present mainly on myeloid cells and gives inhibitory signals when engaged by its ligand CD200. The interaction is currently of therapeutic interest in cancer and inflammation. However functional effects are complicated by the fact that CD200R is itself polymorphic and also a member of a paired receptor family with four closely related gene products in mice called CD200RLa etc. We show that a second allele of CD200R (termed CD200R(2)) that differs in 7 amino acids also binds CD200 but did not react with the widely used CD200R antibody OX110. Biochemical and functional analysis showed that the CD200/CD200R interaction was blocked by the OX131, mAb that recognises both CD200R(1) and CD200R(2), but not by OX110 mAb. Both mAb can give agonistic inhibitory signals but functional analysis shows OX131 mAb also has the potential to block inhibition by preventing the ligand-receptor interaction and hence gives opposing effects. Although OX131 mAb cross-reacts with the activating receptor CD200RLe, it is specific for CD200R in C57BL/6 whilst OX110 mAb cross-reacts on CD200RLc. The results show the importance of the repertoire of paired receptors in strains or individuals and mAb used with implications for paired receptor analysis and therapeutics.
format Online
Article
Text
id pubmed-3653949
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-36539492013-05-20 Dissection of Agonistic and Blocking Effects of CD200 Receptor Antibodies Akkaya, Munir Aknin, Marie-Laure Akkaya, Billur Barclay, A. Neil PLoS One Research Article The CD200 receptor (CD200R) is present mainly on myeloid cells and gives inhibitory signals when engaged by its ligand CD200. The interaction is currently of therapeutic interest in cancer and inflammation. However functional effects are complicated by the fact that CD200R is itself polymorphic and also a member of a paired receptor family with four closely related gene products in mice called CD200RLa etc. We show that a second allele of CD200R (termed CD200R(2)) that differs in 7 amino acids also binds CD200 but did not react with the widely used CD200R antibody OX110. Biochemical and functional analysis showed that the CD200/CD200R interaction was blocked by the OX131, mAb that recognises both CD200R(1) and CD200R(2), but not by OX110 mAb. Both mAb can give agonistic inhibitory signals but functional analysis shows OX131 mAb also has the potential to block inhibition by preventing the ligand-receptor interaction and hence gives opposing effects. Although OX131 mAb cross-reacts with the activating receptor CD200RLe, it is specific for CD200R in C57BL/6 whilst OX110 mAb cross-reacts on CD200RLc. The results show the importance of the repertoire of paired receptors in strains or individuals and mAb used with implications for paired receptor analysis and therapeutics. Public Library of Science 2013-05-14 /pmc/articles/PMC3653949/ /pubmed/23691022 http://dx.doi.org/10.1371/journal.pone.0063325 Text en © 2013 Akkaya et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Akkaya, Munir
Aknin, Marie-Laure
Akkaya, Billur
Barclay, A. Neil
Dissection of Agonistic and Blocking Effects of CD200 Receptor Antibodies
title Dissection of Agonistic and Blocking Effects of CD200 Receptor Antibodies
title_full Dissection of Agonistic and Blocking Effects of CD200 Receptor Antibodies
title_fullStr Dissection of Agonistic and Blocking Effects of CD200 Receptor Antibodies
title_full_unstemmed Dissection of Agonistic and Blocking Effects of CD200 Receptor Antibodies
title_short Dissection of Agonistic and Blocking Effects of CD200 Receptor Antibodies
title_sort dissection of agonistic and blocking effects of cd200 receptor antibodies
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3653949/
https://www.ncbi.nlm.nih.gov/pubmed/23691022
http://dx.doi.org/10.1371/journal.pone.0063325
work_keys_str_mv AT akkayamunir dissectionofagonisticandblockingeffectsofcd200receptorantibodies
AT akninmarielaure dissectionofagonisticandblockingeffectsofcd200receptorantibodies
AT akkayabillur dissectionofagonisticandblockingeffectsofcd200receptorantibodies
AT barclayaneil dissectionofagonisticandblockingeffectsofcd200receptorantibodies